OXALIPLATIN ANTICANCER DRUG ACTION IN EXPERIMENTALLY INDUCED ORAL CARCINOGENESIS BY ASSESSED DNA FLOW CYTOMETRY
Hussein, A., Badawy, M., Mahmoud Mwafey, I., Soliman, O. (2023). OXALIPLATIN ANTICANCER DRUG ACTION IN EXPERIMENTALLY INDUCED ORAL CARCINOGENESIS BY ASSESSED DNA FLOW CYTOMETRY. EKB Journal Management System, 69(1), 167-179. doi: 10.21608/edj.2022.165211.2273
Ahmed Hussein; Mohamed Badawy; Ibraheem Mahmoud Mwafey; Omar Soliman. "OXALIPLATIN ANTICANCER DRUG ACTION IN EXPERIMENTALLY INDUCED ORAL CARCINOGENESIS BY ASSESSED DNA FLOW CYTOMETRY". EKB Journal Management System, 69, 1, 2023, 167-179. doi: 10.21608/edj.2022.165211.2273
Hussein, A., Badawy, M., Mahmoud Mwafey, I., Soliman, O. (2023). 'OXALIPLATIN ANTICANCER DRUG ACTION IN EXPERIMENTALLY INDUCED ORAL CARCINOGENESIS BY ASSESSED DNA FLOW CYTOMETRY', EKB Journal Management System, 69(1), pp. 167-179. doi: 10.21608/edj.2022.165211.2273
Hussein, A., Badawy, M., Mahmoud Mwafey, I., Soliman, O. OXALIPLATIN ANTICANCER DRUG ACTION IN EXPERIMENTALLY INDUCED ORAL CARCINOGENESIS BY ASSESSED DNA FLOW CYTOMETRY. EKB Journal Management System, 2023; 69(1): 167-179. doi: 10.21608/edj.2022.165211.2273

OXALIPLATIN ANTICANCER DRUG ACTION IN EXPERIMENTALLY INDUCED ORAL CARCINOGENESIS BY ASSESSED DNA FLOW CYTOMETRY

Egyptian Dental Journal
Article 3, Volume 69, Issue 1 - Serial Number 3, January 2023, Page 167-179  XML PDF (4.04 MB)
Document Type: Original Article
DOI: 10.21608/edj.2022.165211.2273
View on SCiNiTO View on SCiNiTO
Authors
Ahmed Hussein email orcid 1; Mohamed Badawyorcid 2; Ibraheem Mahmoud Mwafeyorcid 3; Omar Solimanorcid 4
1Department of Oral and Maxillofacial Pathology, Faculty of Dentistry, Assiut University, Assiut, Egypt
2Department of Oral Biology, Faculty of Dentistry, Assiut University, Assiut, Egypt
3Department of Oral Medicine, Periodontology, Oral Diagnosis and Dental Radiology, Faculty of Dentistry, Al-Azhar University (Assiut Branch), Assiut, Egypt
4Department of Oral Medicine, Oral Diagnosis and Periodontology, Faculty of Oral and Dental Medicine, South Valley University, Qena, Egypt
Abstract
Introduction: Oral squamous cell carcinoma is one of the most widespread cancer which totalizes more than 90% of oral malignancies. Therefore, the conception of detaining or preventing the malignant transformation remains a viable target for future. Oxaliplatin is a third-generation platinum based chemotherapy cure that has value in the treatment against several forms of neoplasms. It forms intrastrand links between two adjoining DNA bases, hence disrupting its replication and transcription.
Aim of the study: The current work was carried out to report the oxaliplatin drug as a chemotherapeutic agent during DMBA-induced carcinoma in hamster buccal pouch, utilizing histopathology and flow cytometry analysis.
Material and methods: A total of 60 Syrian hamsters distributed as 2 animals examined for the normal pouch mucosa and 58 hamsters divided into; 6 experiments for Group I, their pouches were painted only with mineral oil. The remaining 52 animals for Group II, treated by DMBA mixed in a mineral oil. After 6 weeks, the hamsters separated into 2 subgroups; Group IIA, were persisted operated in DMBA. Group IIB, were employed to DMBA and injected with oxaliplatin.
Results: Oxaliplatin revealed effectiveness and tolerance in turn down the DMBA carcinogenesis procedure. Additionally, the chemotherapeutic results of oxaliplatin detected a significant reduction relation to the DNA aneuploidy and the S-phase fraction throughout the tumorigenic activity.
Conclusion: Oxaliplatin provided a proper strategy as a chemotherapeutic curing for control oral carcinogenesis process with a notable reduction of cancer incidence through reducing the nuclear proliferation activity and induction of cellular apoptosis.
Keywords
Oral squamous cell carcinoma; Oxaliplatin; Flow Cytometry
Statistics
Article View: 137
PDF Download: 111